JCV serology in time: 3 years of follow-up

High cumulative JC virus seroconversion rate during long-term use of natalizumab

(2016) A. Vennegoor et al.   EUROPEAN JOURNAL OF NEUROLOGY

Re-evaluating the incidence of natalizumab-associated progressive multifocal leukoencephalopathy

(2016) Julian Borchardt et al.   Multiple Sclerosis and Related Disorders

Anti-JC virus seroprevalence in a Finnish MS cohort

(2015) M. Kolasa et al.   ACTA NEUROLOGICA SCANDINAVICA

Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab

(2015) Luisa M. Villar et al.   ANNALS OF NEUROLOGY

PML risk stratification using anti-JCV antibody index and L-selectin

(2015) Nicholas Schwab et al.   Multiple Sclerosis Journal

MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patients

(2015)   Nature Reviews Neurology

PML risk stratification using anti-JCV antibody index and L-selectin

(2015) Nicholas Schwab et al.   Multiple Sclerosis Journal

Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy

(2014) Tatiana Plavina et al.   ANNALS OF NEUROLOGY

Nearly one-half of Brazilian patients with multiple sclerosis using natalizumab are DNA-JC virus positive

(2014) Yara Dadalti Fragoso et al.   ARQUIVOS DE NEURO-PSIQUIATRIA

Anti-JC Virus Antibody Prevalence in Canadian MS Patients

(2014) Virender Bhan et al.   CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES

Progressive multifocal leukoencephalopathy and JC Virus-related disease in modern neurology practice

(2014) Robert L. Carruthers et al.   Multiple Sclerosis and Related Disorders

Anti-JC virus (JCV) antibody prevalence in the JCV Epidemiology in MS (JEMS) trial

(2013) C. Bozic et al.   EUROPEAN JOURNAL OF NEUROLOGY

Anti-JCV Antibodies Detection and JCV DNA Levels in PBMC, Serum and Urine in a Cohort of Spanish Multiple Sclerosis Patients Treated with Natalizumab

(2013) Maria Inmaculada Dominguez-Mozo et al.   Journal of Neuroimmune Pharmacology

JC-virus seroconversion in multiple sclerosis patients receiving natalizumab

(2013) Olivier Outteryck et al.   Multiple Sclerosis Journal

Safety, anxiety and natalizumab continuation in JC virus-seropositive MS patients

(2013) Johannis A van Rossum et al.   Multiple Sclerosis Journal

An assay to quantify species-specific anti-JC virus antibody levels in MS patients

(2013) Clemens Warnke et al.   Multiple Sclerosis Journal

Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort

(2013) Tomas Olsson et al.   Multiple Sclerosis Journal

Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort

(2012) A. K. Trampe et al.   NEUROLOGY

Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: Baseline results of STRATIFY-1

(2011) Carmen Bozic et al.   ANNALS OF NEUROLOGY

Anti-JC virus antibodies: Implications for PML Risk Stratification

(2010) Leonid Gorelik et al.   ANNALS OF NEUROLOGY

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

(2010) David B Clifford et al.   LANCET NEUROLOGY